Abstract :
[en] Introduction: Chondroitin Sulfate (CS) is a drug which is available as pharmaceutical-grade and
nutriceutical-grade products, with important variations in preparation, composition, purity and therapeutic
effects. Previous studies using pharmaceutical-grade CS suggested that the compound
improves pain and function and delays structural progression in knee osteoarthritis (OA), whereas
discrepant results were observed when lower grade preparations were investigated.
Areas covered: The recently published chondroitin versus celecoxib versus Placebo Trial (CONCEPT)
assessed the symptomatic effect of pharmaceutical-grade CS 800 mg/day in symptomatic knee OA.
Expert opinion: This prospective, randomized, 6-month, 3-arm, double-blind, double-dummy, placebo
and celecoxib (200 mg/day) – controlled trial involved 604 patients aged above 50 years with primary
knee OA. This study showed that CS is superior to placebo and similar to celecoxib in reducing pain and
improving function in Kellgren-Lawrence grade 1–3 patients supporting the role of pharmaceuticalgrade
CS as a potential first-line treatment for the management of patients with mild to moderate
knee OA.
Scopus citations®
without self-citations
4